EE9900278A - Angiotensiin II antagonistid kasutamiseks sümptomaatilise südamepuudulikkuse ravis - Google Patents

Angiotensiin II antagonistid kasutamiseks sümptomaatilise südamepuudulikkuse ravis

Info

Publication number
EE9900278A
EE9900278A EEP199900278A EEP9900278A EE9900278A EE 9900278 A EE9900278 A EE 9900278A EE P199900278 A EEP199900278 A EE P199900278A EE P9900278 A EEP9900278 A EE P9900278A EE 9900278 A EE9900278 A EE 9900278A
Authority
EE
Estonia
Prior art keywords
heart failure
angiotensin
symptomatic heart
antagonists
treatment
Prior art date
Application number
EEP199900278A
Other languages
English (en)
Estonian (et)
Inventor
A. Beere Polly
I. Chang Paul
Pitt Bertram
J. Rucinska Ewa
Segal Robert
Sharma Divakar
B. Snavely Duane
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704197.4A external-priority patent/GB9704197D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of EE9900278A publication Critical patent/EE9900278A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
EEP199900278A 1997-01-10 1998-01-07 Angiotensiin II antagonistid kasutamiseks sümptomaatilise südamepuudulikkuse ravis EE9900278A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3492797P 1997-01-10 1997-01-10
GBGB9704197.4A GB9704197D0 (en) 1997-02-28 1997-02-28 Method for reducing mortality with an angiotensin 11 antagonist
PCT/US1998/000534 WO1998030216A1 (fr) 1997-01-10 1998-01-07 Utilisation d'antagonistes d'angiotensine ii dans le traitement d'une insuffisance cardiaque symptomatique

Publications (1)

Publication Number Publication Date
EE9900278A true EE9900278A (et) 2000-02-15

Family

ID=26311085

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900278A EE9900278A (et) 1997-01-10 1998-01-07 Angiotensiin II antagonistid kasutamiseks sümptomaatilise südamepuudulikkuse ravis

Country Status (18)

Country Link
EP (1) EP0966282B1 (fr)
JP (1) JP2000508347A (fr)
KR (1) KR20000070046A (fr)
CN (1) CN1249682A (fr)
AT (1) ATE243515T1 (fr)
AU (1) AU729881B2 (fr)
CA (1) CA2277018C (fr)
DE (1) DE69815822T2 (fr)
DK (1) DK0966282T3 (fr)
EA (1) EA199900635A1 (fr)
EE (1) EE9900278A (fr)
ES (1) ES2200310T3 (fr)
HU (1) HUP0000108A2 (fr)
IL (1) IL130599A0 (fr)
NO (1) NO993399L (fr)
PT (1) PT966282E (fr)
SK (1) SK92899A3 (fr)
WO (1) WO1998030216A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027397A1 (fr) * 1998-11-06 2000-05-18 Glaxo Group Limited Medicaments antihypertenseurs a base de lacidipine et de telmisartan
SE9902597D0 (sv) * 1999-07-06 1999-07-06 Astra Ab New use
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
DK1216038T3 (da) 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
AU3408801A (en) * 2000-02-18 2001-08-27 Takeda Chemical Industries Ltd Tnf-alpha inhibitors
JP2005126338A (ja) * 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
DK3626270T3 (da) * 2013-08-26 2024-01-15 Novartis Ag Behandling af kardiovaskulære sygdomme
BR112018077075A2 (pt) 2016-06-29 2019-04-30 Universite De Montreal heterociclos de biarilmetila

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1142793C (zh) * 1995-06-07 2004-03-24 G·D·瑟尔公司 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰

Also Published As

Publication number Publication date
JP2000508347A (ja) 2000-07-04
ATE243515T1 (de) 2003-07-15
HUP0000108A2 (hu) 2001-04-28
ES2200310T3 (es) 2004-03-01
CN1249682A (zh) 2000-04-05
DE69815822T2 (de) 2004-05-06
EP0966282A1 (fr) 1999-12-29
CA2277018A1 (fr) 1998-07-16
DE69815822D1 (de) 2003-07-31
NO993399L (no) 1999-09-09
PT966282E (pt) 2003-10-31
AU729881B2 (en) 2001-02-15
DK0966282T3 (da) 2003-09-29
KR20000070046A (ko) 2000-11-25
NO993399D0 (no) 1999-07-09
IL130599A0 (en) 2000-06-01
CA2277018C (fr) 2006-10-03
EA199900635A1 (ru) 2000-02-28
SK92899A3 (en) 2000-08-14
WO1998030216A1 (fr) 1998-07-16
EP0966282B1 (fr) 2003-06-25
AU6021898A (en) 1998-08-03

Similar Documents

Publication Publication Date Title
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
NO990916D0 (no) Bruk av GLP-1 eller analoger i behandlingen av myokardialt infarkt
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
BR9609066A (pt) Antagonista aldoesterone epoxi-esteroidal e terapia de combinação de antagonista angiotensina ii para tratamento de deficiência do coração
PT998287E (pt) Utilizacao de levobupivacaina
TR200102958T2 (tr) Siklooksijenaz-2 inhibitörleri olarak 4,5-diaril-3(2H)-furanon türevleri.
DK1572230T3 (da) Placenta alkalisk phosphatase til at kontrollere diabetes
ATE232865T1 (de) 1,4-diazabicyclo(3.2.2)nonan-4-carboxylat und carboxamidderivate, ihre herstellung und therapeutische verwendung
WO1999017755A3 (fr) Medicaments
TR200101470T2 (tr) Farmasötik bileşim terkipleri.
BR9915134A (pt) Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição
DE69826684D1 (de) Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendungen
DE69831938D1 (de) Beschichtete, implantierbare medizinische geräte
DK0966282T3 (da) Anvendelse af angiotensin ll antagonister til behandling af symptomatisk hjerteinsufficiens
TR199701536T1 (xx) Benzimidazollerin, l�seminin tedavisi i�in bir ila� �retilmesinde kullan�m�.
DK165982C (da) Imidazolylguanidinderivater og laegemidler, der indeholder disse forbindelser
DK1478362T3 (da) Kombinationsbehandling til akut myokardisk infarkt
CA2091134A1 (fr) Agent therapeutique contre les risques d'avortement
ES2166816T3 (es) Derivados piridil-imidazolicos y procedimientos para su preparacion.
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
TR199701617T1 (xx) �iftliklerde �retilen bal�klarda g�r�len parazitlerle m�cadelede kullan�lacak bir ajan.
SE0101328D0 (sv) Therapeutic treatment
Prakash et al. Brachial plexus with two trunks and double axillary veins: applied importance and clinical implications
MD980129A (en) Antiherpetic remedy